» Articles » PMID: 38066936

Provoked Vs Minimally Provoked Vs Unprovoked VTE: Does It Matter?

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Venous thromboembolism (VTE) is a multifactorial disease, and its risk depends on exposure to risk factors and predisposing conditions. Based on their strength of association with a VTE episode, risk factors are classified as major or minor and determined using a temporal pattern to be transient or persistent. All patients with VTE should receive anticoagulant treatment for at least 3 months in the absence of an absolute contraindication. Beyond this period, selected patients may be candidates for an extended phase of anticoagulation aimed at secondary VTE prevention. The risk of recurrent VTE if anticoagulation is discontinued is probably the main driver of decision-making regarding extended treatment. The risk of recurrence after VTE associated with major risk factors is low if the risk factor is no longer present. In this case, treatment can be discontinued. If the major risk factor is persistent, anticoagulation should be continued. After VTE occurring in the absence of risk factors, anticoagulation should probably be continued indefinitely if the risk for bleeding is low and preferably with minimal effective doses of anticoagulants. VTE occurring after exposure to minor risk factors is probably the most challenging situation, especially if the clinical manifestation was acute pulmonary embolism. Understanding the actual role of minor risk factors in the occurrence of VTE helps in estimating the risk of recurrence and avoiding the dangers associated with unnecessary anticoagulation. The availability of safer strategies for anticoagulation could allow personalized strategies for secondary prevention of VTE.

Citing Articles

Decision theoretical foundations of clinical practice guidelines: an extension of the ASH thrombophilia guidelines.

Djulbegovic B, Hozo I, Guyatt G Blood Adv. 2024; 8(13):3596-3606.

PMID: 38625997 PMC: 11319831. DOI: 10.1182/bloodadvances.2024012931.


Biomarkers Profile in Provoked Unprovoked Deep Venous Thrombosis.

Tavares I, Caffaro R, Portugal M, Ribeiro C, da Silva V, Krupa E Clin Appl Thromb Hemost. 2024; 30:10760296241238211.

PMID: 38566607 PMC: 10989034. DOI: 10.1177/10760296241238211.


Venous thromboembolism: diagnostic advances and unaddressed challenges in management.

Mathews R, Hinds M, Nguyen K Curr Opin Hematol. 2024; 31(3):122-129.

PMID: 38359323 PMC: 10977858. DOI: 10.1097/MOH.0000000000000809.

References
1.
De Caterina R, Prisco D, Eikelboom J . Factor XI inhibitors: cardiovascular perspectives. Eur Heart J. 2022; 44(4):280-292. DOI: 10.1093/eurheartj/ehac464. View

2.
Albertsen I, Nielsen P, Sogaard M, Goldhaber S, Overvad T, Rasmussen L . Risk of Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. Am J Med. 2018; 131(9):1067-1074.e4. DOI: 10.1016/j.amjmed.2018.04.042. View

3.
Konstantinides S, Meyer G, Becattini C, Bueno H, Geersing G, Harjola V . 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2019; 41(4):543-603. DOI: 10.1093/eurheartj/ehz405. View

4.
Verso M, Munoz A, Connors J . Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive. Intern Emerg Med. 2023; 18(6):1619-1634. DOI: 10.1007/s11739-023-03306-8. View

5.
Grewal K, Atzema C, Sutradhar R, Everett K, Horner D, Thompson C . Venous Thromboembolism in Patients Discharged From the Emergency Department With Ankle Fractures: A Population-Based Cohort Study. Ann Emerg Med. 2021; 79(1):35-47. DOI: 10.1016/j.annemergmed.2021.06.017. View